Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases
- 1 July 2009
- journal article
- editorial
- Published by Elsevier in Experimental Neurology
- Vol. 218 (1) , 5-8
Abstract
No abstract availableThis publication has 60 references indexed in Scilit:
- Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouseExperimental Neurology, 2009
- Enzyme Replacement Improves Ataxic Gait and Central Nervous System Histopathology in a Mouse Model of Metachromatic LeukodystrophyMolecular Therapy, 2009
- Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in miceJournal of Lipid Research, 2008
- Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouseProceedings of the National Academy of Sciences, 2007
- Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluidMolecular Genetics and Metabolism, 2007
- Clinical response to persistent, low‐level β‐glucuronidase expression in the murine model of mucopolysaccharidosis type VIIJournal of Inherited Metabolic Disease, 2007
- Central Nervous System-directed AAV2/5-Mediated Gene Therapy Synergizes with Bone Marrow Transplantation in the Murine Model of Globoid-cell LeukodystrophyMolecular Therapy, 2007
- Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseasesJournal of Experimental Medicine, 2006
- Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapyGlycobiology, 2004
- Butanedione treatment reduces receptor binding of a lysosomal enzyme to cells and membranesBiochemical and Biophysical Research Communications, 1980